(NVO) Novo Nordisk - Ratings and Ratios

Novo Nordisk A/S (NYSE:NVO) is a global healthcare leader specializing in the research, development, and distribution of innovative pharmaceutical solutions. Headquartered in Bagsvaerd, Denmark, the company operates in two primary segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment focuses on treatments for diabetes, obesity, and cardiovascular conditions, while the Rare Disease segment addresses rare blood and endocrine disorders. Novo Nordisk is renowned for its insulin pens, growth hormone pens, and injection needles, as well as digital health solutions like smart insulin pens and the Dose Check app for insulin dose management. The company has strategic collaborations, including a partnership with UNICEF to combat childhood obesity and a joint initiative with Valo Health, Inc. to develop novel cardiometabolic therapies. Founded in 1923, Novo Nordisk has established itself as a pioneer in diabetes care, with a strong commitment to innovation and patient-centric solutions. Web URL: https://www.novonordisk.com.

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based multinational pharmaceutical company with a market capitalization of $263.69 billion. The company trades on the NYSE under the ticker symbol NVO, classified under the Pharmaceuticals sub-industry. Its stock is currently priced at $58.08, with a 20-day average volume of 8,075,250 shares. The stocks resistance levels are at 77.9, 65.4, and 59.8. Key technical indicators include an SMA20 of 66.66, SMA50 of 76.17, and SMA200 of 103.82, with an ATR of 3.13. On the fundamental side, the company reports a P/E ratio of 19.68, a forward P/E of 16.18, a P/B ratio of 13.78, and a P/S ratio of 0.91. Novo Nordisk also boasts a return on equity (RoE) of 70.38%, reflecting strong profitability.